Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
äŒæ¥ã³ãŒãETON
äŒç€ŸåEton Pharmaceuticals Inc
äžå Žæ¥Nov 09, 2018
æé«çµå¶è²¬ä»»è
ãCEOãBrynjelsen (Sean E)
åŸæ¥å¡æ°31
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Nov 09
æ¬ç€Ÿæåšå°21925 W Field Pkwy Ste 235
éœåžDEER PARK
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·60010-7278
é»è©±çªå·18477877361
ãŠã§ããµã€ãhttps://etonpharma.com/
äŒæ¥ã³ãŒãETON
äžå Žæ¥Nov 09, 2018
æé«çµå¶è²¬ä»»è
ãCEOãBrynjelsen (Sean E)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã